Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations

Int J Hematol. 2022 Jun;115(6):915. doi: 10.1007/s12185-022-03350-8. Epub 2022 Apr 9.

Authors

Gerold Thölking^{1

2}, Ulrich Jehn², Stefan Reuter³

Affiliations

¹ Department of Internal Medicine and Nephrology, University Hospital of Münster Marienhospital Steinfurt, Steinfurt, Germany.
² Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, Münster, Germany.
³ Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, Münster, Germany. stefan.reuter@ukmuenster.de.

PMID: 35396676
DOI: 10.1007/s12185-022-03350-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Cytochrome P-450 CYP3A
Cytochrome P-450 CYP3A Inhibitors* / pharmacology
Humans
Immunosuppressive Agents / pharmacology
Tacrolimus*
Voriconazole

Substances

Cytochrome P-450 CYP3A Inhibitors
Immunosuppressive Agents
Cytochrome P-450 CYP3A
Voriconazole
Tacrolimus